

# Inhaltsverzeichnis

Zusammenfassung	13
Einleitung	13
Methode	14
Feststellungen	14
Folgerungen und Empfehlungen	15
Zusammenfassung	16
Abstract	17
Introduction	17
Method	18
Results	18
Conclusions and Recommendations	19
Summary	19
1. Introduction	21
1.1 Techniker Krankenkasse – RAND Collaboration and Initial Study	21
1.2 Objectives and Research Questions for the Present Study	21
1.3 Rationale	22
1.4 Summary of Key Findings	22
1.5 Organization of the Remainder of the Report	24
2. Background: Chronic Diseases and their Treatment	25
2.1 Diabetes	25
2.2 Hypertension	26
2.3 Lipid Disorders	27
2.4 Comorbidities	29
2.5 Metabolic Syndrome	29
2.6 Summary	30

3. Methods	31
3.1 Data Sources	31
3.2 Sample Selection	32
3.3 Data Transformations for the Identifications of Comorbidities	33
3.4 Study Samples	35
3.5 Baseline Characteristics of the Analytical Samples	36
3.5.1 Treated Diabetes	36
3.5.2 Treated Hypertension	37
3.5.3 Treated Lipid Disorders	38
3.6 Methods for Comparative Assessment	39
4. Prevalence and treatment of comorbidities among Treated diabetic patients and Health Care use and Spending	41
4.1 The Sample of Patients with Treated Diabetes in Germany and the US	41
4.2 Prevalence of Comorbidities among Treated Diabetics	43
4.3 Treatment of Comorbidities among Treated Diabetics	45
4.4 Medical Care Utilization	47
4.4.1 Outpatient Care	47
4.4.2 Inpatient Care	48
4.5 Medical Care Spending	49
4.5.1 Total Medical Spending	49
4.5.2 Outpatient Spending	51
4.5.3 Inpatient Spending	52
4.5.4 Prescription Drug Spending	54
5. Prevalence and treatment of comorbidities among Treated Hypertension patients and Health Care use and Spending	56
5.1 The Sample of Patients with Treated Hypertension in Germany and the US	56
5.2 Prevalence of Comorbidities among Patients with Treated Hypertension	57
5.3 Treatment of Comorbidities among Treated Hypertensives	59
5.4 Medical Care Utilization	61
5.4.1 Outpatient Care	61
5.4.2 Inpatient Care	62
5.5 Medical Care Spending	63
5.5.1 Total Medical Spending	63
5.5.2 Outpatient Spending	65

5.5.3	Inpatient Spending	66
5.5.4	Prescription Drug Spending	67
6.	Prevalence and treatment of comorbidities among Treated Lipid Disorder patients and Health Care use and Spending	70
6.1	The Sample of Patients with Treated Lipid Disorders in Germany and the US	70
6.2	Prevalence of Comorbidities among Patients with Treated Lipid Disorders	71
6.3	Treatment of Comorbidities among Patients with a Treated Lipid Disorder	73
6.4	Medical Care Utilization	75
6.4.1	Outpatient Care	75
6.4.2	Inpatient Care	76
6.5	Medical Care Spending	77
6.5.1	Total Medical Spending	77
6.5.2	Outpatient Spending	79
6.5.3	Inpatient Spending	80
6.5.4	Prescription Drug Spending	81
7.	Disease Transitions: Dynamic Extensions	83
7.1	Onset of Comorbidities	83
7.1.1	Patients with Treated Diabetes	83
7.1.1.1	Onset of Hypertension Among Patients with Treated Diabetes	83
7.1.1.2	Onset of Lipid Disorder Among Patients with Treated Diabetes	85
7.1.2	Patients with Treated Hypertension	87
7.1.2.1	Onset of Diabetes Among Patients with Treated Hypertension	87
7.1.2.2	Onset of Lipid Disorder Among Patients with Treated Hypertension	89
7.1.3	Treated Lipid Disorders	91
7.1.3.1	Onset of Diabetes Among Patients with Treated Lipid Disorders	91
7.1.3.2	Onset of Hypertension Among Patients with Treated Lipid Disorders	93
7.2	Onset of Complications	95
7.2.1	Treated Diabetes	95
7.2.1.1	Onset of Cardiac Disease	95

7.2.1.2	Onset of Central Nervous System Disease	97
7.2.1.3	Onset of Ocular Disease	99
7.2.1.4	Peripheral Neuropathy	100
7.2.1.5	Onset of Peripheral Vascular Disease	102
7.2.1.6	Renal Disease	104
7.2.2	Treated Hypertension	105
7.2.2.1	Onset of Cardiac Disease	105
7.2.2.2	Onset of Central Nervous System Disease	107
7.2.2.3	Onset of Ocular Disease	109
7.2.2.4	Onset of Peripheral Neuropathy	110
7.2.2.5	Onset of Peripheral Vascular Disease	112
7.2.2.6	Onset of Renal Disease	114
7.2.3	Treated Lipid Disorder	115
7.2.3.1	Onset of Cardiac Disease	115
7.2.3.2	Onset of Central Nervous System Disease	117
7.2.3.3	Onset of Ocular Disease	119
7.2.3.4	Onset of Peripheral Neuropathy	120
7.2.3.5	Onset of Peripheral Vascular Disease	122
7.2.3.6	Onset of Renal Disease	124

8.	Discussion	126
----	------------	-----

8.1	Summary of the Baseline Analysis	126
8.1.1	Comorbidities and their Pharmacological Treatment	126
8.1.2	Health care use and spending	127
8.2	Summary of Transitions into Comorbidities and Complications	128
8.2.1	Comorbidities	128
8.2.2	Complications	128
8.3	Limitations	129
8.3.1	Sample selection	129
8.3.2	Data coding and patient classification	129
8.3.3	Modeling issues	130
	References	131

Appendices	133
------------	-----

A4.	Appendix with Supporting Material for Chapter 4 (Treated Diabetes)	133
	Prevalence of Comorbidities among Patients with Treated Diabetes	133
	Treatment of Comorbidities Among Patients with Treated Diabetes	135

Medical Care Utilization among Patients with Treated Diabetics	136
Medical Care Spending Among Patients with Treated Diabetes	138
A5. Appendix with Supporting Material for Chapter 5 (Treated Hypertension)	141
Prevalence of Comorbidities among Patients with Treated Hypertension	141
Treatment of Comorbidities Among Patients with Treated Diabetes	142
Medical Care Utilization among Patients with Treated Hypertension	144
Medical Care Spending Among Patients with Treated Hypertension	146
A6. Appendix with Supporting Material for Chapter 6 (Treated Lipid Disorder)	149
Prevalence of Comorbidities among Patients with a Treated Lipid Disorder	150
Treatment of Comorbidities Among Patients with a Treated Lipid Disorder	151
Medical Care Utilization among Patients with a Treated Lipid Disorder	153
Medical Care Spending Among Patients with a Treated Lipid Disorder	155
A7. Appendix with Supporting Material for Chapter 7 (Disease Transitions)	159
Prävalenz und Demografie chronisch kranker Versicherter ohne indikationsspezifische pharmakotherapeutische Versorgung – Addendum –	161
1. Einleitung	161
2. Methodik	162
3. Ergebnisse	163
3.1 Diabetes mellitus	164
3.2 Hypertonie	166
3.3 Dyslipidämie	168
4. Diskussion und Ausblick	170
Literatur	173
Authors	177